ArticleBMJ public health2025
Epidemiological trends and economic burden of genital warts in Dutch primary care.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to describe the epidemiological trends and estimate the economic burden of genital warts (GW) in Dutch primary care. Methods: A retrospective, non-interventional, multiyear study (2011-2021) was performed using data from the Nivel Primary Care Database. Changes in incidence by age group, sex and level of urbanisation of individuals with GW and associated healthcare resource use (general practitioner consultations, prescribed medication and referrals) were estimated over the 11-year period. Total annual healthcare costs and cost per incident case were estimated via a bottom-up gross costing approach. Results: Between 2011 and 2021, GW incidence increased, which was especially seen in men (from 2.0 to 3.5 per 1000 inhabitants) and to a lesser extent in women (from 1.9 to 2.1 per 1000 inhabitants). GW incidence was most common in age group 20-29 years (men: 43.6%; women: 50.7%) and highly urbanised areas. Medication was prescribed in 61.4% of GW cases, and 5.4% of patients with GW were referred to secondary care. Total costs in Dutch primary care increased by 108% from €2.3 million in 2011 to €4.9 million in 2021. The cost per incident case also showed an increasing trend from €72 in 2011 to €99 in 2021. Referrals to secondary care resulted in a 14%-30% increase in total costs. Conclusions: This study provides novel insights into recent epidemiological trends of GW and its associated costs in Dutch primary care. The incidence of GW increased particularly among men, and the total annual costs of GW in primary care doubled between 2011 and 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.